Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of “Buy” from Analysts

by · The Markets Daily

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating on the company.

BAYRY has been the topic of several recent research reports. Morgan Stanley raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Zacks Research lowered shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th.

Check Out Our Latest Analysis on BAYRY

Bayer Aktiengesellschaft Stock Up 0.1%

Bayer Aktiengesellschaft stock opened at $10.82 on Friday. The stock has a 50 day moving average of $9.14 and a two-hundred day moving average of $8.40. Bayer Aktiengesellschaft has a twelve month low of $4.83 and a twelve month high of $10.97. The stock has a market capitalization of $42.52 billion, a price-to-earnings ratio of -120.21, a PEG ratio of 5.40 and a beta of 0.66. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.04.

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

Featured Stories